鞘内泵市场：2026-2032年全球市场预测（按泵类型、药物类型、治疗领域和最终用户划分）

预计到 2025 年，鞘内帮浦市场价值将达到 17.3 亿美元，到 2026 年将成长至 18.6 亿美元，到 2032 年将达到 31.5 亿美元，复合年增长率为 8.88%。

主要市场统计数据
基准年 2025	17.3亿美元
预计年份：2026年	18.6亿美元
预测年份 2032	31.5亿美元
复合年增长率 (%)	8.88%

权威说明概述了鞘内泵疗法的发展历程、临床重点、监管期望以及影响其实施的相关人员决策因素。

鞘内泵疗法已从一种小众临床干预手段发展成为全身性治疗无效或副作用难以接受时，治疗复杂疼痛和痉挛的核心工具。在过去十年间，临床医生拓展了其适应症并优化了患者选择标准，而工程师则提高了设备的可靠性、药物传输的精确度和可编程性。因此，鞘内泵生态系统如今已成为众多相关人员的交汇点，包括植入医生、设备製造商、医院采购团队、门诊中心、保险公司以及寻求持续症状控制并降低全身风险的患者。

设备工程、远端监测、临床实践和监管预期等方面的创新融合，将如何重塑部署路径和护理服务模式？

由于技术、临床实践和医疗服务模式等多面向因素的融合，鞘内帮浦领域正经历着变革性的转变。设备层面的创新优先考虑耐用性和精准性，电池和导管介面的逐步改进正在降低再次手术率并提高患者的便利性。同时，远端监测和数位遥测技术的整合能够更早发现设备相关併发症并更快地调整剂量，最终影响后续工作流程和临床资源的分配。

详细分析了 2025 年价格调整如何迫使供应链快速调整、筹资策略和设计变更，以保护临床连续性和获利能力。

2025年的贸易政策变化和关税调整为鞘内泵的供应链和筹资策略带来了新的不稳定性。某些医疗设备组件和进口子组件关税的提高，推高了依赖地理分散生产网路的製造商的投入成本。为因应这一变化，各组织加快了供应商多元化策略，重新评估了采购地点，并优先选择在前置作业时间和价格方面提供更高透明度和柔软性的供应商合约。除了这些供应方面的应对措施外，各组织还采取了营运方面的调整，例如增加关键导管和电子元件的库存缓衝，以及更严格的组件认证流程。

全面的细分洞察揭示了医疗设备类型、药物选择、治疗适应症和医疗保健环境如何相互交织，从而决定临床工作流程和商业化策略。

了解治疗效果和商业化路径需要对鞘内泵的市场结构进行深入观点，包括产品和临床细分。根据帮浦的类型，治疗方案可分为两类：用于短期或住院治疗的体外输注系统和用于长期慢性鞘内治疗的植入式帮浦。每种帮浦都有其独特的易用性、感染控制和维护的考量。这些器械类别决定了临床医生的工作流程，并影响治疗的开展地点。植入式系统通常需要在手术环境下进行，并需要长期随访，而体外装置则通常适用于急性期或过渡期治疗。

关键区域见解解释了美洲、欧洲、中东和非洲以及亚太地区在监管、偿还和基础设施现实方面的差异如何影响部署和准入策略。

区域趋势正在影响整个鞘内帮浦领域的临床应用、监管互动和供应链设计。在美洲，紧密的学术机构和地方医院网络，以及强有力的核准后临床研究，促进了早期应用。这些地区复杂的报销机制和支付方的严格审查影响着申办者对证据产生的优先排序。同时，一体化的医院系统能够建构支援长期追踪和设备维护的整合式诊疗路径。因此，製造商越来越倾向于根据医疗系统的证据需求和价值验证试点计画来调整其打入市场策略。

从公司层面深入分析，揭示了成熟製造商和创新新参与企业如何透过临床证据、服务模式和软体驱动的差异化竞争。

鞘内帮浦市场的竞争动态反映了现有设备的可靠性与新兴的、针对特定临床需求的专业创新者之间的平衡。成熟的製造商凭藉长期的临床数据、广泛的服务网络和综合培训项目保持优势，这些优势能够降低植入风险并支持后续护理。这些优势有助于建立机构信任，并简化医院和专科诊所的采购决策，因为这些机构的临床团队需要高可靠性和完善的售后支援。

为医疗设备製造商、临床医生和支付方提供实用建议，以协调证据、数位化能力、供应链弹性和经营模式，以实现永续成长。

产业领导者需要采取果断行动，使产品蓝图、临床证据产生和供应链韧性与不断发展的医疗服务模式保持一致。应优先进行整合价值论证，将医疗设备性能与具有临床意义的结局联繫起来，例如减少全身用药、降低住院率以及改善痉挛患者的功能状态。儘早与支付方和大规模医疗系统合作，并制定切实可行的证据收集倡议，可以缩短报销审核週期，并支持基于价值的合约试点专案。

为了确保获得可操作的见解，我们采用透明、严谨的调查方法，结合了对临床医生的访谈、监管和文献审查、供应链分析以及专家检验。

本研究整合了多种调查方法，以确保研究结果的严谨性和可重复性。在初步调查中，我们对实施植入手术的医生、采购经理和临床专案经理进行了结构化访谈，以了解实际操作情况、患者选择标准和后续工作流程。除了这些第一线人员的观点外，临床顾问小组的讨论检验了临床假设，并确定了在不同医疗环境中推广鞘内治疗的实际障碍。

简洁的结论强调了在创造临床价值、确保供应弹性以及使证据与支付方和提供者的需求保持一致方面所面临的策略挑战。

鞘内帮浦治疗正处于转折点，临床潜力、技术能力和政策趋势在此交汇，为相关人员创造了新的机会和责任。设备设计和遥测技术的进步正在推动更安全、以患者为中心的护理模式的发展，而不断提高的支付方期望和监管审查则要求提供更强有力的证据和更完善的生命週期管理。 2025年的定价经验凸显了分散式供应链的脆弱性，以及製定策略性弹性规划以确保治疗连续性的必要性。

目录

第一章：序言

第二章：调查方法

• 调查设计
• 研究框架
• 市场规模预测
• 数据三角测量
• 调查结果
• 调查的前提
• 研究限制

第三章执行摘要

• 首席主管观点
• 市场规模和成长趋势
• 2025年市占率分析
• FPNV定位矩阵，2025
• 新的商机
• 下一代经营模式
• 产业蓝图

第四章 市场概览

• 产业生态系与价值链分析
• 波特五力分析
• PESTEL 分析
• 市场展望
• 上市策略

第五章 市场洞察

• 消费者洞察与终端用户观点
• 消费者体验基准
• 机会映射
• 分销通路分析
• 价格趋势分析
• 监理合规和标准框架
• ESG与永续性分析
• 中断和风险情景
• 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 鞘内帮浦市场：依帮浦类型划分

• 外置泵
• 嵌入式泵浦

第九章：按药物类型分類的鞘内泵市场

• Baclofen
• 局部麻醉剂
• 阿片类药物

第十章：依治疗领域分類的鞘内帮浦市场

• 疼痛管理
  • 癌症疼痛
  • 慢性非癌性疼痛
• 痉挛管理
  • 脑性麻痹
  • 多发性硬化症
  • 脊髓损伤

第十一章 鞘内帮浦市场：依最终用户划分

• 门诊手术中心
• 医院
• 专科诊所

第十二章 鞘内帮浦市场：依地区划分

• 北美洲和南美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十三章 鞘内帮浦市场：依组别划分

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十四章 鞘内帮浦市场：依国家划分

• 我们
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十五章：美国鞘内帮浦市场

第十六章：中国鞘内帮浦市场

第十七章 竞争格局

• 市场集中度分析，2025年
  • 浓度比（CR）
  • 赫芬达尔-赫希曼指数 (HHI)
• 近期趋势及影响分析，2025 年
• 2025年产品系列分析
• 基准分析，2025 年
• Abbott Laboratories
• Arrow International, Inc.
• Arthrex, Inc.
• B. Braun Melsungen AG
• Baxter International Inc.
• Becton Dickinson and Company
• Boston Scientific Corporation
• Durect Corporation
• Flowonix Medical, Inc.
• Fresenius Kabi AG
• Johnson & Johnson Services Inc.
• Medallion Therapeutics, Inc.
• Medtronic plc
• Smiths Medical
• Teleflex Inc.
• Terumo Corporation
• Tricumed Medizintechnik GmbH
• Zimmer Biomet Holdings, Inc.

The Intrathecal Pumps Market was valued at USD 1.73 billion in 2025 and is projected to grow to USD 1.86 billion in 2026, with a CAGR of 8.88%, reaching USD 3.15 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 1.73 billion
Estimated Year [2026]	USD 1.86 billion
Forecast Year [2032]	USD 3.15 billion
CAGR (%)	8.88%

An authoritative introduction that frames intrathecal pump therapy evolution, clinical priorities, regulatory expectations, and stakeholder decision drivers shaping adoption

Intrathecal pump therapy has matured from a niche clinical intervention to a central tool for managing complex pain and spasticity when systemic therapies fail or cause unacceptable side effects. Over the past decade clinicians have expanded indications and refined patient selection, while technologists have improved device reliability, drug delivery precision, and programmability. As a result, the intrathecal pump ecosystem now intersects diverse stakeholders: implanting physicians, device manufacturers, hospital procurement teams, ambulatory centers, payers, and patients seeking durable symptom control with fewer systemic risks.

The introduction of advanced infusion algorithms and integrated telemetric monitoring has shifted discussions from simply whether to use intrathecal delivery toward how to optimize long-term therapy in outpatient settings. Concurrently, regulatory agencies have sharpened focus on post-market surveillance and device-human interface risks, prompting manufacturers to invest in clinical evidence and lifecycle management. Taken together, these developments demand that clinical leaders and commercial strategists navigate a more complex environment where safety, outcomes, service, and cost-efficiency determine adoption trajectories rather than device novelty alone.

This executive summary synthesizes the clinical, commercial, and policy dynamics shaping intrathecal pump therapy today. It frames the transformational shifts influencing stakeholder decisions, highlights tariff-driven supply chain implications for 2025, and distills segmentation, regional, and competitive insights actors must consider. The goal is to provide a coherent, actionable foundation for executives and clinical leaders to align product development, market access, and operational strategies with evolving patient and system needs.

How converging innovations in device engineering, remote monitoring, clinical practices, and regulatory expectations are reshaping adoption pathways and care delivery models

The intrathecal pump landscape is undergoing transformative shifts driven by converging forces in technology, clinical practice, and healthcare delivery models. Device-level innovation has prioritized longevity and precision; batteries and catheter interfaces have seen incremental improvements that reduce revision rates and improve patient convenience. Simultaneously, the integration of remote monitoring and digital telemetry is enabling earlier detection of device-related complications and more responsive dose titration, which in turn influences follow-up workflows and clinic resource allocation.

Clinical practice is shifting from episodic in-clinic programming to hybrid monitoring models that combine periodic in-person assessments with data-driven remote adjustments. This evolution supports broader use of ambulatory surgical centers for implantation and follow-up, altering traditional hospital-centered referral patterns. At the same time, heightened attention to opioid stewardship and growing evidence for intrathecal baclofen in spasticity care have expanded conversations around patient selection criteria and long-term management pathways. These clinical shifts are creating new expectations for evidence generation, patient education, and multidisciplinary care coordination.

Regulatory and reimbursement environments are also evolving. Agencies are prioritizing robust post-market surveillance and clearer labeling on device-drug combinations, requiring manufacturers to demonstrate lifecycle safety. Payers are scrutinizing long-term value propositions more closely, looking beyond acute procedural costs to outcomes such as reduction in systemic drug use, hospitalization, and caregiver burden. As a result, commercial strategies increasingly emphasize real-world evidence collection, value-based contracting pilots, and partnerships with health systems to demonstrate integrated care pathways that support both clinical outcomes and economic objectives.

Taken together, these transformative shifts are reshaping not just product roadmaps but also the operational and commercial architectures required to scale intrathecal therapies. Effective stakeholders will be those that harmonize device performance with care delivery innovations and evidence generation to lower barriers to adoption and secure long-term therapeutic partnerships with providers and payers.

A focused analysis of how 2025 tariff shifts forced rapid supply chain adaptation, procurement strategies, and design changes to protect clinical continuity and margins

Trade policy changes and tariff adjustments in 2025 introduced a new variable into intrathecal pump supply chains and procurement strategies. Increased duties on select medical device components and imported subassemblies elevated input costs for manufacturers that rely on geographically distributed production networks. In response, organizations accelerated supplier diversification strategies, re-evaluated sourcing footprints, and prioritized supplier contracts that provide greater transparency and flexibility around lead times and pricing. These supply-side responses have been complemented by operational changes such as increased inventory buffers for critical catheter and electronic components and more rigorous component qualification processes.

Clinicians and hospital procurement teams observed the downstream effects through intermittent lead-time extensions and more frequent allocation prioritization for urgent cases. Ambulatory surgical centers reported heightened attention to stock management as shorter-term suppliers struggled to absorb tariff-related cost pressures. In parallel, some manufacturers implemented targeted price adjustments or revised service contracts to offset increased input costs while protecting access to essential therapies for high-acuity patients.

Policy uncertainty surrounding tariff permanence encouraged several strategic pivots that may endure beyond 2025. Manufacturers intensified nearshoring and localization efforts to reduce exposure to cross-border duties, while contract manufacturers expanded capacities in lower-tariff jurisdictions. Additionally, there was accelerated interest in design-for-supply resilience, where component standardization and modularization reduce dependence on single-source, tariff-exposed parts. These adaptations improved medium-term supply continuity but also required capital investment and cross-functional coordination, affecting short-term margins and product rollout timelines.

For healthcare leaders, the lesson from the 2025 tariff environment is that supply chain resilience is now a strategic dimension of clinical continuity planning. Procurement teams and device sponsors increasingly collaborate on contingency planning, including dual-sourcing strategies and visibility into upstream supplier risk. As tariff volatility persists as a planning consideration, organizations that embed flexible sourcing, buffer strategies, and proactive supplier engagement into their operating models will be better positioned to sustain therapy availability and protect patient care pathways.

Comprehensive segmentation insights revealing how device type, drug selection, therapeutic indication, and care setting intersect to determine clinical workflows and commercialization tactics

Understanding outcomes and commercialization pathways requires a granular view of the product and clinical segmentation that structures the intrathecal pump landscape. Based on pump type, the therapeutic continuum spans externally wearable infusion systems intended for short-term or hospital-based use and implantable pumps designed for chronic long-term intrathecal therapy, each presenting distinct usability, infection control, and maintenance considerations. These device categories inform clinician workflows and influence where care is delivered; implantable systems typically demand surgically oriented settings and long-term follow-up infrastructure, whereas external devices often align to acute or transitional care episodes.

Drug formulation and compatibility directly shape clinical protocols and labeling. Based on drug type, intrathecal therapy incorporates agents such as baclofen for targeted spasticity control, local anesthetics that permit regional analgesia, and opioids deployed for refractory cancer and severe chronic pain. Each drug class brings unique tolerance profiles, dosing paradigms, and monitoring requirements, and clinicians calibrate device programming and follow-up frequency to mitigate risks like catheter-related granulomas or systemic adverse effects. The selection of an intrathecal agent therefore tightly couples pharmacology with device selection and patient counseling.

Therapeutic application further refines care pathways. Based on therapy area, intrathecal interventions serve pain management and spasticity management domains. Pain management itself divides into cancer pain and chronic noncancer pain, with implant choice, opioid stewardship practices, and palliative care integration differing substantially between these populations. Spasticity management encompasses conditions such as cerebral palsy, multiple sclerosis, and spinal cord injury, each with distinct functional goals, multidisciplinary care needs, and long-term rehabilitation implications. Tailoring device features and service models to these clinical subpopulations enhances adherence and functional outcomes.

End-user dynamics are equally influential for deployment and service models. Based on end user, adoption pathways include ambulatory surgical centers, hospitals, and specialty clinics, each carrying different operational capabilities, reimbursement environments, and staffing models. Ambulatory surgical centers are increasingly attractive for elective implant procedures due to efficiency and patient preference, whereas hospitals often manage more medically complex cases and perioperative risks. Specialty clinics that provide longitudinal device programming and multidisciplinary follow-up are essential for maintaining therapy effectiveness and capturing outcomes data. Recognizing how these segmentation lenses intersect is critical for designing go-to-market approaches, clinician education programs, and long-term service offerings that align with real-world care delivery.

Key regional insights explaining how distinct regulatory, reimbursement, and infrastructure realities across the Americas, EMEA, and Asia-Pacific shape adoption and access strategies

Regional dynamics influence clinical adoption, regulatory engagement, and supply chain design across the intrathecal pump landscape. In the Americas, a dense network of academic centers and community hospitals has supported early adoption combined with robust post-approval clinical research. This region's reimbursement complexity and payer scrutiny influence how sponsors prioritize evidence generation, while consolidated hospital systems enable integrated care pathways that support long-term follow-up and device maintenance. Consequently, manufacturers often align market access strategies with health system evidence needs and value demonstration pilots.

Europe, the Middle East, and Africa present heterogeneous regulatory and reimbursement environments that compel flexible market-entry strategies. Western European countries generally emphasize comparative effectiveness and health technology assessment frameworks, prompting manufacturers to invest in real-world outcomes and cost-effectiveness studies. In contrast, parts of the Middle East and Africa may prioritize access and infrastructure development, creating opportunities for targeted capacity-building programs and local partnerships. Cross-border regulatory harmonization efforts and centralized procurement mechanisms in certain jurisdictions can accelerate technology adoption when evidence and service support are aligned.

Asia-Pacific exhibits a mix of mature markets with established regulatory pathways and emerging markets characterized by rapid investment in specialty care infrastructure. In advanced economies within the region, clinical innovators and private healthcare systems drive demand for high-performance devices and integrated service models. In emerging markets, demand is often shaped by investments in surgical capacity, changing disease burdens, and localized reimbursement decisions. Manufacturers seeking regional scale frequently adopt hybrid approaches that combine direct presence in mature markets with distributor partnerships and training programs in developing markets to ensure appropriate clinical adoption and continuity of care.

Across regions, common themes emerge: the necessity of local evidence generation, the importance of training clinical teams for implantation and follow-up, and the value of supply chain resilience. Tailoring commercial and clinical strategies to regional regulatory, payer, and infrastructural realities accelerates adoption while ensuring therapies remain accessible and clinically effective across diverse healthcare systems.

Key company-level insights showing how established manufacturers and innovative entrants compete through clinical evidence, service models, and software-enabled differentiation

Competitive dynamics in the intrathecal pump space reflect a balance between incumbent device reliability and the emergence of specialized innovators targeting niche clinical needs. Established manufacturers maintain advantages through long-term clinical data, extensive service networks, and integrated training programs that reduce implantation risk and support follow-up care. These capabilities foster institutional trust and simplify procurement decisions for hospitals and specialty clinics where clinical teams demand high reliability and robust post-market support.

At the same time, newer entrants and adjacent medical technology firms are differentiating through software-enabled features, remote monitoring, and modular design concepts that emphasize ease of programming and reduced maintenance burden. Such offerings appeal to health systems focused on outpatient care models and to specialists seeking finer titration capabilities. Collaboration between device developers and pharmaceutical sponsors has also intensified, particularly for drug-device combination strategies where co-development can streamline labeling and clinical trial design.

Service and commercial models are increasingly central to competitive positioning. Companies that offer comprehensive clinician training, local technical support, and transparent warranty and replacement policies create stickiness in clinical pathways. Additionally, vendors that invest in outcomes registries and real-world evidence initiatives build stronger value narratives with payers and health systems. Strategic partnerships with hospitals, academic centers, and rehabilitation networks further extend reach and support adoption by embedding devices within established care pathways.

For buyers and health system leaders, vendor selection now hinges on a broader set of criteria than device features alone. Total cost of therapy, service quality, evidence commitments, and the ability to collaborate on pathway redesign have become equally important. Consequently, suppliers that integrate clinical support, data services, and flexible commercial arrangements are better positioned to capture long-term partnerships and scale intrathecal therapy within complex care delivery ecosystems.

Actionable recommendations for device makers, clinicians, and payers to align evidence, digital capabilities, supply resilience, and commercial models for sustainable growth

Industry leaders must act decisively to align product roadmaps, clinical evidence generation, and supply chain resilience with evolving care delivery models. First, prioritize integrated value demonstrations that link device performance to clinically meaningful outcomes such as reduced systemic medication use, lower hospitalization rates, and improved functional status for spasticity patients. Engaging payers and large health systems early to design pragmatic evidence collection initiatives will shorten reimbursement deliberations and support value-based contracting pilots.

Second, invest in remote monitoring and telemetric capabilities that enable hybrid follow-up models and reduce the frequency of in-person visits without compromising safety. Remote data streams not only enhance patient convenience but also provide real-world endpoints that strengthen economic narratives. Complement these technical investments with clinician training programs that prepare broader surgical and specialty clinic networks to adopt implantation and programming protocols, which will expand suitable care settings beyond tertiary centers.

Third, build supply chain strategies that emphasize dual sourcing, localized manufacturing where feasible, and design-for-supply approaches that reduce dependence on tariff-exposed components. Strategic inventory management and supplier partnerships can buffer against short-term disruptions while preserving margins. Simultaneously, cultivate partnerships with rehabilitation and palliative care providers to embed intrathecal therapy within multidisciplinary care pathways, thereby improving patient identification and continuity of care.

Finally, structure commercial models around service and outcomes, not just hardware sales. Offer flexible contracting, warranty packages, and outcomes-based components where feasible to align incentives with purchasers. By integrating evidence generation, digital capabilities, and resilient operations into a coherent go-to-market strategy, industry leaders will be better equipped to scale therapies while addressing payer scrutiny and clinician expectations.

A transparent and rigorous research methodology combining clinician interviews, regulatory and literature review, supply chain analysis, and expert validation to ensure actionable insights

This research synthesizes multiple methodologies to ensure rigorous, reproducible insights. Primary research included structured interviews with implanting physicians, procurement leaders, and clinical program managers to capture operational realities, patient selection criteria, and follow-up workflows. These first-hand perspectives were complemented by clinician advisory panel discussions that validated clinical assumptions and highlighted practical barriers to scaling intrathecal therapies in diverse care settings.

Secondary research encompassed regulatory documentation, peer-reviewed clinical literature, and procedural best-practice guidelines to triangulate safety signals and device performance themes. Product technical specifications and service model descriptions were analyzed to identify emerging design trends and vendor capabilities. Additionally, analysis of clinical registry abstracts and published outcomes studies informed the synthesis of therapeutic and safety narratives specific to baclofen therapy, local anesthetic use, and opioid-based intrathecal interventions.

Supply chain and policy analysis drew on customs and trade publications, publicly available tariff schedules, and procurement case studies to assess the operational impact of 2025 tariff changes. Scenario analysis techniques were applied to evaluate plausible supply-side responses, including nearshoring, dual sourcing, and inventory strategies, and to understand their implications for manufacturers and healthcare providers. Throughout the study, findings were validated through cross-functional expert review to ensure practical relevance and factual accuracy.

The research approach prioritized transparency and reproducibility. Data gaps were documented and addressed through follow-up interviews or conservative interpretation, and limitations are clearly delineated to support appropriate application of insights. This methodological rigor ensures that conclusions are grounded in current clinical practice, regulatory realities, and operational constraints faced by stakeholders in the intrathecal pump ecosystem.

A concise conclusion highlighting the strategic imperatives for capturing clinical value, ensuring supply resilience, and aligning evidence with payer and provider needs

Intrathecal pump therapy stands at an inflection point where clinical promise, technological capability, and policy dynamics converge to create new opportunities and responsibilities for stakeholders. Advances in device design and telemetry are enabling safer, more patient-centric care models, while evolving payer expectations and regulatory attention demand stronger evidence and lifecycle stewardship. The 2025 tariff experience underscored the fragility of distributed supply chains and the strategic necessity of resilience planning to protect therapy continuity.

Segmentation across pump type, drug selection, therapy area, and end-user setting highlights that successful adoption depends on aligning product features with clinical workflows and support services. Regional differences in regulatory expectations and infrastructure further require tailored market approaches. Competitive differentiation is increasingly determined by the quality of service, evidence generation, and digital integration rather than hardware specifications alone.

Looking ahead, stakeholders that integrate robust real-world evidence programs, invest in remote monitoring, and fortify supply chain flexibility will be best positioned to expand access and demonstrate long-term value. Collaboration across manufacturers, clinical networks, and payers will accelerate adoption pathways and ensure that intrathecal therapies deliver meaningful outcomes for patients with complex pain and spasticity needs.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Intrathecal Pumps Market, by Pump Type

• 8.1. External Pumps
• 8.2. Implantable Pumps

9. Intrathecal Pumps Market, by Drug Type

• 9.1. Baclofen
• 9.2. Local Anesthetics
• 9.3. Opioids

10. Intrathecal Pumps Market, by Therapy Area

• 10.1. Pain Management
  • 10.1.1. Cancer Pain
  • 10.1.2. Chronic Noncancer Pain
• 10.2. Spasticity Management
  • 10.2.1. Cerebral Palsy
  • 10.2.2. Multiple Sclerosis
  • 10.2.3. Spinal Cord Injury

11. Intrathecal Pumps Market, by End User

• 11.1. Ambulatory Surgical Centers
• 11.2. Hospitals
• 11.3. Specialty Clinics

12. Intrathecal Pumps Market, by Region

• 12.1. Americas
  • 12.1.1. North America
  • 12.1.2. Latin America
• 12.2. Europe, Middle East & Africa
  • 12.2.1. Europe
  • 12.2.2. Middle East
  • 12.2.3. Africa
• 12.3. Asia-Pacific

13. Intrathecal Pumps Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Intrathecal Pumps Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. United States Intrathecal Pumps Market

16. China Intrathecal Pumps Market

17. Competitive Landscape

• 17.1. Market Concentration Analysis, 2025
  • 17.1.1. Concentration Ratio (CR)
  • 17.1.2. Herfindahl Hirschman Index (HHI)
• 17.2. Recent Developments & Impact Analysis, 2025
• 17.3. Product Portfolio Analysis, 2025
• 17.4. Benchmarking Analysis, 2025
• 17.5. Abbott Laboratories
• 17.6. Arrow International, Inc.
• 17.7. Arthrex, Inc.
• 17.8. B. Braun Melsungen AG
• 17.9. Baxter International Inc.
• 17.10. Becton Dickinson and Company
• 17.11. Boston Scientific Corporation
• 17.12. Durect Corporation
• 17.13. Flowonix Medical, Inc.
• 17.14. Fresenius Kabi AG
• 17.15. Johnson & Johnson Services Inc.
• 17.16. Medallion Therapeutics, Inc.
• 17.17. Medtronic plc
• 17.18. Smiths Medical
• 17.19. Teleflex Inc.
• 17.20. Terumo Corporation
• 17.21. Tricumed Medizintechnik GmbH
• 17.22. Zimmer Biomet Holdings, Inc.

LIST OF FIGURES

• FIGURE 1. GLOBAL INTRATHECAL PUMPS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL INTRATHECAL PUMPS MARKET SHARE, BY KEY PLAYER, 2025
• FIGURE 3. GLOBAL INTRATHECAL PUMPS MARKET, FPNV POSITIONING MATRIX, 2025
• FIGURE 4. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 5. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 7. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 9. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 11. UNITED STATES INTRATHECAL PUMPS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 12. CHINA INTRATHECAL PUMPS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

• TABLE 1. GLOBAL INTRATHECAL PUMPS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 2. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
• TABLE 3. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY EXTERNAL PUMPS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 4. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY EXTERNAL PUMPS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 5. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY EXTERNAL PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 6. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY IMPLANTABLE PUMPS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 7. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY IMPLANTABLE PUMPS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 8. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY IMPLANTABLE PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 9. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 10. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY BACLOFEN, BY REGION, 2018-2032 (USD MILLION)
• TABLE 11. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY BACLOFEN, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 12. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY BACLOFEN, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 13. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY LOCAL ANESTHETICS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 14. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY LOCAL ANESTHETICS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 15. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY LOCAL ANESTHETICS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 16. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 17. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY OPIOIDS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 18. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 19. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
• TABLE 20. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 21. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 22. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 23. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
• TABLE 24. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY CANCER PAIN, BY REGION, 2018-2032 (USD MILLION)
• TABLE 25. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY CANCER PAIN, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 26. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY CANCER PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 27. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY CHRONIC NONCANCER PAIN, BY REGION, 2018-2032 (USD MILLION)
• TABLE 28. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY CHRONIC NONCANCER PAIN, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 29. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY CHRONIC NONCANCER PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 30. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 31. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 32. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 33. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2032 (USD MILLION)
• TABLE 34. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY CEREBRAL PALSY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 35. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY CEREBRAL PALSY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 36. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY CEREBRAL PALSY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 37. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 38. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 39. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 40. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPINAL CORD INJURY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 41. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPINAL CORD INJURY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 42. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPINAL CORD INJURY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 43. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 44. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 45. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 46. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 47. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 48. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 49. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 50. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 51. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 52. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 53. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 54. AMERICAS INTRATHECAL PUMPS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 55. AMERICAS INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
• TABLE 56. AMERICAS INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 57. AMERICAS INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
• TABLE 58. AMERICAS INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
• TABLE 59. AMERICAS INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2032 (USD MILLION)
• TABLE 60. AMERICAS INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 61. NORTH AMERICA INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 62. NORTH AMERICA INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
• TABLE 63. NORTH AMERICA INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 64. NORTH AMERICA INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
• TABLE 65. NORTH AMERICA INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
• TABLE 66. NORTH AMERICA INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2032 (USD MILLION)
• TABLE 67. NORTH AMERICA INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 68. LATIN AMERICA INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 69. LATIN AMERICA INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
• TABLE 70. LATIN AMERICA INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 71. LATIN AMERICA INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
• TABLE 72. LATIN AMERICA INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
• TABLE 73. LATIN AMERICA INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2032 (USD MILLION)
• TABLE 74. LATIN AMERICA INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 75. EUROPE, MIDDLE EAST & AFRICA INTRATHECAL PUMPS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 76. EUROPE, MIDDLE EAST & AFRICA INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
• TABLE 77. EUROPE, MIDDLE EAST & AFRICA INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 78. EUROPE, MIDDLE EAST & AFRICA INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2032 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 82. EUROPE INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 83. EUROPE INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
• TABLE 84. EUROPE INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 85. EUROPE INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
• TABLE 86. EUROPE INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
• TABLE 87. EUROPE INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2032 (USD MILLION)
• TABLE 88. EUROPE INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 89. MIDDLE EAST INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 90. MIDDLE EAST INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
• TABLE 91. MIDDLE EAST INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 92. MIDDLE EAST INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
• TABLE 93. MIDDLE EAST INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
• TABLE 94. MIDDLE EAST INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2032 (USD MILLION)
• TABLE 95. MIDDLE EAST INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 96. AFRICA INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 97. AFRICA INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
• TABLE 98. AFRICA INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 99. AFRICA INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
• TABLE 100. AFRICA INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
• TABLE 101. AFRICA INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2032 (USD MILLION)
• TABLE 102. AFRICA INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 103. ASIA-PACIFIC INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 104. ASIA-PACIFIC INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
• TABLE 105. ASIA-PACIFIC INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 106. ASIA-PACIFIC INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
• TABLE 107. ASIA-PACIFIC INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
• TABLE 108. ASIA-PACIFIC INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2032 (USD MILLION)
• TABLE 109. ASIA-PACIFIC INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 110. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 111. ASEAN INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 112. ASEAN INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
• TABLE 113. ASEAN INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 114. ASEAN INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
• TABLE 115. ASEAN INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
• TABLE 116. ASEAN INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2032 (USD MILLION)
• TABLE 117. ASEAN INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 118. GCC INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 119. GCC INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
• TABLE 120. GCC INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 121. GCC INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
• TABLE 122. GCC INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
• TABLE 123. GCC INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2032 (USD MILLION)
• TABLE 124. GCC INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 125. EUROPEAN UNION INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 126. EUROPEAN UNION INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
• TABLE 127. EUROPEAN UNION INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 128. EUROPEAN UNION INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
• TABLE 129. EUROPEAN UNION INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
• TABLE 130. EUROPEAN UNION INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2032 (USD MILLION)
• TABLE 131. EUROPEAN UNION INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 132. BRICS INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 133. BRICS INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
• TABLE 134. BRICS INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 135. BRICS INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
• TABLE 136. BRICS INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
• TABLE 137. BRICS INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2032 (USD MILLION)
• TABLE 138. BRICS INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 139. G7 INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 140. G7 INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
• TABLE 141. G7 INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 142. G7 INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
• TABLE 143. G7 INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
• TABLE 144. G7 INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2032 (USD MILLION)
• TABLE 145. G7 INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 146. NATO INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 147. NATO INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
• TABLE 148. NATO INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 149. NATO INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
• TABLE 150. NATO INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
• TABLE 151. NATO INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2032 (USD MILLION)
• TABLE 152. NATO INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 153. GLOBAL INTRATHECAL PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 154. UNITED STATES INTRATHECAL PUMPS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 155. UNITED STATES INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
• TABLE 156. UNITED STATES INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 157. UNITED STATES INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
• TABLE 158. UNITED STATES INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
• TABLE 159. UNITED STATES INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2032 (USD MILLION)
• TABLE 160. UNITED STATES INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 161. CHINA INTRATHECAL PUMPS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 162. CHINA INTRATHECAL PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
• TABLE 163. CHINA INTRATHECAL PUMPS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 164. CHINA INTRATHECAL PUMPS MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
• TABLE 165. CHINA INTRATHECAL PUMPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
• TABLE 166. CHINA INTRATHECAL PUMPS MARKET SIZE, BY SPASTICITY MANAGEMENT, 2018-2032 (USD MILLION)
• TABLE 167. CHINA INTRATHECAL PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)